hTNFa-Tg

Fig.1 Detection of hTNFα expression in serum by ELISA (male, 8-12wks, n=2). 

Abbr. WT, wild type.

Note. hTNFα-Tg and C57BL/6 mice were i.p. injected with LPS for 2h.

Fig.2 Detection of mTnfα expression in serum by ELISA (male, 8-12wks, n=2). 

Abbr. WT, wild type.

Note. hTNFα-Tg and C57BL/6 mice were i.p. injected with LPS.

Fig.3 Body Weight of hTNFα-Tg (male, 5-6wks, n=10).

Fig4. Clinical score of joint swelling in hTNFa-Tg mice and representative diagram of hind limb joints of mice in each group on day 94. 

Fig.5 Clinical score of joint swelling hTNFα mice (male, 5-6wks, n=10).

Signs of arthritis were assessed by a visual score where 0 = Normal paw, 1 = one toe inflamed or swollen, 2 = more than one toe, but not entire paw, or mild swelling of the entire paw, 3 = entire paw inflamed and swollen, and 4 = very inflamed and swollen paw or ankylosed paw.

Fig.6 Micro-CT image of hTNFα-Tg mice. hTNFα-Tg mice have significant articular bone flow type.

Fig.7 Micro-CT image of hTNFα-Tg mice. The tibia of hTNFα-Tg mice shows no significant difference.

Fig.8 Score of hTNFα-Tgmice (A) and H&E pathology(B). (male)

Compared with the WT C57BL/6, the mixed inflammatory cell infiltration in hTNFα-Tg mice is significantly increased, with obvious proliferation of synovial joints, formation of pannus, fibroblast tissue production, and cartilage erosion.

Fig.9 In Vivo Efficacy study of Infliximab (anti-TNFα) in hTNFα-Tg Rheumatoid Arthritis Mouse Model. 

Infliximab was administrated via i.p. injection every week from 8 weeks old. (A) Clinical score and (B) feet thickness (n=6) of hTNFα -Tg Rheumatoid Arthritis Mouse Model. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig.10  In Vivo Efficacy study of Infliximab (anti-TNFα) in hTNFα-Tg Rheumatoid Arthritis Mouse Model. 

Infliximab was administrated via i.p. injection every week from 8 weeks old. (A) Body weight and (B) body weight change of hTNFα-Tg Rheumatoid Arthritis Mouse Model. (n=10). Mean ± SEM. t-test.

Fig.11 In Vivo Efficacy study of Infliximab (anti-TNFα) in hTNFα-Tg Rheumatoid Arthritis Mouse Model. 

Infliximab was administrated via i.p. injection every week fro 8 weeks. Representative three-dimensional images of ankle joint of each group in hTNFα-Tg Rheumatoid Arthritis Mouse Model. 

Fig.12 In Vivo Efficacy study of Infliximab (anti-TNFα) in hTNFα-Tg Rheumatoid Arthritis Mouse Model. 

Infliximab was administrated via i.p. injection every week from 14 weeks old. (A) Clinical score and (B) feet thickness (n=6) of hTNFα-Tg Rheumatoid Arthritis Mouse Model. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig.13 In Vivo Efficacy study of Infliximab (anti-TNFα) in hTNFα-Tg Rheumatoid Arthritis Mouse Model.

Infliximab was administrated via i.p. injection every week from 14 weeks old. (A) Body weight and (B) body weight change of hTNFα-Tg Rheumatoid Arthritis Mouse Model. (n=10). Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.